HUBBARD, Ohio, June 13, 2012 /PRNewswire/ -- NanoLogix (OTC Markets:NNLX) announced today its R&D team in collaboration with University of Texas Health Science Center - Houston (UTHSC-Houston) researchers, are developing a multi-well, microplate reader variant of the company’s BioNanoFilter (BNF) diagnostics for use in large volume laboratory environments. Early analysis of the multi-well plates shows exceptionally fast live-threat results similar to the company’s standard BNF technology. Starting this week, the NanoLogix BNF and BioNanoPore (BNP) technology will be on exhibit at booth #841 at the 112th General Meeting of the American Society for Microbiology in San Francisco, June 16 June 19.
(Photo: http://photos.prnewswire.com/prnh/20120613/CL23734)
Research using NanoLogix technology from a recently completed clinical study will also be presented at the ASM General Meeting on June 17th. Dr. Jonathan Faro of UTHSC-Houston will present the research, which focused on detection, identification, and determination of antibiotic sensitivity of Group B Streptococcus (GBS) during pregnancy. Data showed NanoLogix diagnostics consistently provided results in a 4 to 6 hour window, dramatically shorter than standard culturing times of 48 to 72 hours. The data and the associated clinical study narrative is currently being formatted for submission for peer-review publication, as well as to the US FDA for acceptance as a non-invasive diagnostic technology.
“These are exciting times for NanoLogix,” said CEO Bret Barnhizer. “Our technology has the potential to dramatically affect the course of human health and events over the past eight months have greatly enhanced our position for the future.”
Rapid Live-Threat Tuberculosis Results
Recent R&D operations have also converged to dramatically enrich NanoLogix’ bacteria and protozoa detection technology portfolio.
The detection for Tuberculosis (TB) utilizing NanoLogix’ BNF and BioNanoPore (BNP) technologies has recently been completed by a major independent, third-party research laboratory. Live-threat TB was detected with NanoLogix BNP technology in 4 to 5 days, as opposed to 21 to 84 days with standard culture. TB was also detected and identified with the company’s BNF technology in less than two hours. Peer-reviewed publication and FDA submittal are in process for results from both BNP and BNF Tuberculosis research.
“We are thrilled to be dramatically cutting bacterial detection times from days to hours for many pathogens,” said Barnhizer. “Specifically, we have reduced wait times for TB from weeks to days, while protozoa detection times for Cryptosporidium, which is responsible for over 50 percent of waterborne illnesses, have been cut from weeks to hours. At the same time, we have been able to accomplish these results with improved quality of detection.”
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit www.nanologix.com.
Media Contact:
Lisa Ann Pinkerton
Technica Communications for NanoLogix
408-806-9626
lisaann@technicacommunications.com
Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
carol@nanologix.com
This press release contains statements, which may constitute “forward- looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
SOURCE NanoLogix, Inc.
